| Trial Identifier: | D8242C00001 |
| Sponsor: | AstraZeneca |
| NCTID:: | NCT05205161 |
| Start Date: | July 2022 |
| Primary Completion Date: | August 2023 |
| Study Completion Date: | August 2023 |
| Condition: | Non-Hodgkin's Lymphoma |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
| Language | Description |
| English Version | |
| Spanish Translation | |
| French Translation | |
| Italian Translation | |
| Korean Translation | |
| Portuguese Translation |
| Country | Location |
|---|---|
| AU | Heidelberg, AU, 3084 |
| ES | Palma de Mallorca, ES, 07010 |
| ES | Pamplona, ES, 31008 |
| ES | Salamanca, ES, 37007 |
| FR | LILLE CEDEX, FR, 59037 |
| IT | Milan, IT, 20141 |
| KR | Seoul, KR, 03080 |
| KR | Seoul, KR, 6591 |
| PT | Porto, PT, 4200-072 |
| US, CA | Duarte, CA, US, 91010 |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company